Feb 25, 2021
ReForm Biologics Expands Focus to Develop In-house Pipeline of Bio-innovative Medicines WOBURN, Mass. – February 25, 2021– ReForm Biologics today announced it will expand its focus to develop a new generation of bio-innovative biologic medicines in-house to improve...
Feb 23, 2021
VANCOUVER, Wash., Feb. 22, 2021 /PRNewswire/ — AbSci, a pioneering synthetic biology company that unifies biologic drug discovery and development processes, today announced a strategic equity investment by Merck Global Health Innovation Fund (Merck GHI) and...
Feb 5, 2021
Infectious diseases diagnostics company Lucira Health Inc. launched an IPO of 9 million shares of common stock at $17 per share, for expected gross proceeds of $153 million. Friday’s Wall Street debut was a show of confidence, upsized from an original plan to offer...
Feb 5, 2021
EMERYVILLE, Calif.–(BUSINESS WIRE) Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced the pricing of its...
Feb 5, 2021
Infectious diseases diagnostics company Lucira Health Inc. launched an IPO of 9 million shares of common stock at $17 per share, for expected gross proceeds of $153 million. Friday’s Wall Street debut was a show of confidence, upsized from an original plan to offer...
